Literature DB >> 27930338

Pegylated IFN-α suppresses hepatitis C virus by promoting the DAPK-mTOR pathway.

Wei-Liang Liu1,2, Hung-Chih Yang3,4, Ching-Sheng Hsu5,6, Chih-Chiang Wang1, Tzu-San Wang1, Jia-Horng Kao7,3,8, Ding-Shinn Chen7,3,8,9.   

Abstract

Death-associated protein kinase (DAPK) has been found to be induced by IFN, but its antiviral activity remains elusive. Therefore, we investigated whether DAPK plays a role in the pegylated IFN-α (peg-IFN-α)-induced antiviral activity against hepatitis C virus (HCV) replication. Primary human hepatocytes, Huh-7, and infectious HCV cell culture were used to study the relationship between peg-IFN-α and the DAPK-mammalian target of rapamycin (mTOR) pathways. The activation of DAPK and signaling pathways were determined using immunoblotting. By silencing DAPK and mTOR, we further assessed the role of DAPK and mTOR in the peg-IFN-α-induced suppression of HCV replication. Peg-IFN-α up-regulated the expression of DAPK and mTOR, which was associated with the suppression of HCV replication. Overexpression of DAPK enhanced mTOR expression and then inhibited HCV replication. In addition, knockdown of DAPK reduced the expression of mTOR in peg-IFN-α-treated cells, whereas silencing of mTOR had no effect on DAPK expression, suggesting mTOR may be a downstream effector of DAPK. More importantly, knockdown of DAPK or mTOR significantly mitigated the inhibitory effects of peg-IFN-α on HCV replication. In conclusion, our data suggest that the DAPK-mTOR pathway is critical for anti-HCV effects of peg-IFN-α.

Entities:  

Keywords:  DAPK; PAK-1; hepatitis C virus; mTOR; peg-IFN-α

Mesh:

Substances:

Year:  2016        PMID: 27930338      PMCID: PMC5187687          DOI: 10.1073/pnas.1618517114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Diagnosis, management, and treatment of hepatitis C.

Authors:  Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

2.  p21-activated kinase 1 is activated through the mammalian target of rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis C virus in human hepatoma cells.

Authors:  Hisashi Ishida; Kui Li; Minkyung Yi; Stanley M Lemon
Journal:  J Biol Chem       Date:  2007-01-25       Impact factor: 5.157

3.  Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway.

Authors:  Xinying Zhou; Yijin Wang; Herold J Metselaar; Harry L A Janssen; Maikel P Peppelenbosch; Qiuwei Pan
Journal:  J Hepatol       Date:  2014-05-22       Impact factor: 25.083

Review 4.  Hepatitis in 2010: the dawn of a new era in HCV therapy.

Authors:  Sandra Ciesek; Michael P Manns
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

5.  mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression.

Authors:  Bilgen Ekim; Brian Magnuson; Hugo A Acosta-Jaquez; Jennifer A Keller; Edward P Feener; Diane C Fingar
Journal:  Mol Cell Biol       Date:  2011-05-16       Impact factor: 4.272

6.  The Akt proto-oncogene links Ras to Pak and cell survival signals.

Authors:  Y Tang; H Zhou; A Chen; R N Pittman; J Field
Journal:  J Biol Chem       Date:  2000-03-31       Impact factor: 5.157

Review 7.  Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.

Authors:  Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2011-05       Impact factor: 17.425

8.  The pro-apoptotic function of death-associated protein kinase is controlled by a unique inhibitory autophosphorylation-based mechanism.

Authors:  G Shohat; T Spivak-Kroizman; O Cohen; S Bialik; G Shani; H Berrisi; M Eisenstein; A Kimchi
Journal:  J Biol Chem       Date:  2001-09-28       Impact factor: 5.157

9.  Akt phosphorylation of serine 21 on Pak1 modulates Nck binding and cell migration.

Authors:  Guo-Lei Zhou; Ya Zhuo; Charles C King; Benjamin H Fryer; Gary M Bokoch; Jeffrey Field
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

10.  Integrative functional genomics of hepatitis C virus infection identifies host dependencies in complete viral replication cycle.

Authors:  Qisheng Li; Yong-Yuan Zhang; Stephan Chiu; Zongyi Hu; Keng-Hsin Lan; Helen Cha; Catherine Sodroski; Fang Zhang; Ching-Sheng Hsu; Emmanuel Thomas; T Jake Liang
Journal:  PLoS Pathog       Date:  2014-05-22       Impact factor: 6.823

View more
  4 in total

1.  Regulation of the Expression of DAPK1 by SUMO Pathway.

Authors:  Qingshui Wang; Xiuli Zhang; Ling Chen; Shuyun Weng; Yun Xia; Yan Ye; Ke Li; Ziqiang Liao; Pengchen Chen; Khaldoon Alsamman; Chen Meng; Craig Stevens; Ted R Hupp; Yao Lin
Journal:  Biomolecules       Date:  2019-04-17

2.  Superior Antitumor Efficacy of IFN-α2b-Incorporated Photo-Cross-Linked Hydrogels Combined with T Cell Transfer and Low-Dose Irradiation Against Gastric Cancer.

Authors:  Qin Liu; Dinghu Zhang; Hanqing Qian; Yanhong Chu; Yan Yang; Jie Shao; Qiuping Xu; Baorui Liu
Journal:  Int J Nanomedicine       Date:  2020-05-27

3.  Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection.

Authors:  Vishnu Venugopal; Pranesh Padmanabhan; Rubesh Raja; Narendra M Dixit
Journal:  PLoS Comput Biol       Date:  2018-07-12       Impact factor: 4.475

4.  DAPK1 (death associated protein kinase 1) mediates mTORC1 activation and antiviral activities in CD8+ T cells.

Authors:  Zhengping Wei; Pingfei Li; Ran He; Huicheng Liu; Na Liu; Yu Xia; Guoyu Bi; Qiuyang Du; Minghui Xia; Lei Pei; Jing Wang; Guihua Wang; Zhao-Hui Tang; Xiang Cheng; Huabin Li; Zhuoya Li; Lilin Ye; Arian Laurence; Youming Lu; Xiang-Ping Yang
Journal:  Cell Mol Immunol       Date:  2019-09-20       Impact factor: 11.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.